Peripheral nerve complications of HIV-1 infection …

Ravindra Kumar Garg DM FRCP

Peripheral Neuropathies

Updated 12.27.2023
Released 06.21.2004
Expires For CME 12.27.2026

Peripheral nerve complications of HIV-1 infection

Author: Ravindra Kumar Garg DM FRCP

See Contributor Disclosures

Editor: Louis H Weimer MD

Peripheral nerve complications of HIV-1 infection

In This Article

Quick Link

Introduction

Overview

Although the entire neuraxis is susceptible, the most common neurologic complications of HIV-1 involve the peripheral nervous system. In addition to painful sensory neuropathy, other types of neuropathy seen are AIDP, CIDP, autonomic neuropathy, polyradiculopathy, mononeuropathies, mononeuritis multiplex, cranial neuropathies, and ALS-like motor neuropathy. With the advent of highly active antiretroviral therapy (HAART), the incidence of most neurologic complications has declined; however, the incidence of peripheral neuropathy has increased, with distal sensory polyneuropathy and antiretroviral toxic neuropathy being the most frequently reported forms. Abnormalities in the calcium/calmodulin-dependent protein kinase (CAMKK2) gene predispose to HIV-associated distal sensory peripheral neuropathy. Additional studies have identified genetic markers and polymorphisms that may predict susceptibility to HIV-associated sensory and autonomic neuropathy, even among patients on successful antiretroviral therapy. Volumetric assessment of brain has revealed that atrophied posterior cingulate cortex is associated with neuropathic pain. An observation noted that declining neurocognitive performance was associated with worsened neuropathic pain in patients with HIV-associated peripheral neuropathy. A functional magnetic resonance imaging-based study revealed a role of increased anterior insula activation in the pathogenesis of HIV neuropathic pain. Changes in the spectrum of gut microbiota are also thought to play a role in the pathogenesis of HIV neuropathic pain. Neuropathic pain is a disabling complication for which no satisfactory treatment is currently available. A Cochrane review failed to demonstrate efficacy of pregabalin in HIV neuropathy. Substantial reduction in the prevalence of distal sensory peripheral neuropathy takes place following combination antiretroviral treatment in treatment-naïve people with HIV. In this update, the author reviews the latest findings on the clinical presentation, management, and pathogenesis of these and other peripheral nerve complications of HIV-1 infection.

Key points

	• Peripheral nerve complications are one the most common neurologic complication of HIV infection.
	• HIV associated neuropathy is either because of the disease itself or to toxicity of antiretroviral therapy.
	• HIV associated neuropathy leads to significant morbidity and significantly affects daily activities.
	• In addition to painful sensory neuropathy, other types of neuropathy seen are AIDP, CIDP, autonomic neuropathy, polyradiculopathy, mononeuropathies, mononeuritis multiplex, cranial neuropathies, and ALS-like motor neuropathy.
	• Current treatment for disabling neuropathic pain is far from satisfactory.
	• Drugs used for neuropathic pain include gabapentin, lamotrigine, pregabalin, amitriptyline, duloxetine, and high-dose topical capsaicin patches.

Historical note and terminology

Incidence. Neurologic complications of HIV-1 have been reported for over 20 years (28; 148), and it is widely appreciated that the entire neuraxis is susceptible to complications. With the advent of HAART and prolonged survival, the incidence of most neurologic complications has declined; however, the incidence of distal sensory polyneuropathy has increased, with distal sensory polyneuropathy and antiretroviral toxic neuropathy remaining the most frequently reported neurologic manifestations. Other peripheral nerve complications include acute or chronic demyelinating neuropathies, mononeuritis or mononeuritis multiplex, autonomic neuropathy, and polyradiculopathy (24).

In retrospective studies of patients with acquired immune deficiency syndrome, the incidence of peripheral neuropathy syndromes is estimated to be 10% (210; 131). When including patients with electrophysiologic evidence of polyneuropathy who lack clinical symptoms of peripheral neuropathy, the incidence rises to 40% (103; 212). This figure increases to 48% to 100% in pathologic studies (54; 140).

Prospective series reveal an incidence of peripheral neuropathy of 5% to 60%, depending on the disease stage and neuropathy definition (212; 32; 91; 99; 07; 193; 65). A study of 252 patients enrolled in a pre-HAART trial of HIV-infected individuals with memory complaints and CD4 counts less than 300 found a prevalence rate of 20% for asymptomatic neuropathy and 35% for symptomatic neuropathy. The estimated incidence rate of symptomatic distal sensory neuropathy was 36% after 12 months and 52% after 24 months (193). In the age of HAART therapy, the same group found the 1-year incidence of symptomatic distal sensory neuropathy decreased to 21% (194).

In a cross-sectional study from Uganda, among 800 participants (400 HIV- and 400 HIV+), neuropathy was present in 13% of the participants. Neuropathy was more common in HIV+ patients (19% vs. 7%, respectively). Older age significantly increased the risk of neuropathy in patients with HIV infection (192). HIV-infected pediatric patients are also vulnerable for peripheral neuropathy. In rural South Africa, 182 HIV-infected children on antiretroviral therapy were assessed for peripheral neuropathy. Symptoms of neuropathy were present in 48 children (28%), and signs were noted in 25 children (14%). A diagnosis of peripheral neuropathy was confirmed in 42 children (24%). Risk factors were co-trimoxazole prophylaxis and didanosine use (166). In another cross-sectional study, which included 383 Tanzanian HIV-positive children, peripheral neuropathy was detected in 14.1% of the children. Low CD4 cell count, high viral load, an ART regime containing a non-nucleoside reverse transcriptase inhibitor and protease inhibitors, and exposure to isoniazid predicted peripheral neuropathy in these children (03).

When approaching the diagnosis and management of these complications, it is essential to determine four things: (1) the specific localization of the lesion (ie, spinal cord, nerve root, plexus, peripheral nerve, or multiple peripheral nerves); (2) the staging of the HIV infection (determined by the total CD4+ lymphocyte cell count, the total HIV viral load, and the patient’s clinical condition); (3) the patient’s medication regimen; and (4) the presence of concomitant disease processes.

Clinical manifestations

Presentation and course

The spectrum of clinical manifestations is wide given that the peripheral nerve can be affected at any point from the level of the root to the most distal small, unmyelinated fibers. The etiology of the findings is usually due to a direct effect of HIV itself, opportunistic infections, neoplasms, or medication toxicity. The clinical presentation and etiology of the reported HIV complications of the peripheral nervous system will be considered individually, moving from the root level distally to the peripheral nerve.

Polyradiculopathy. HIV-related lumbosacral polyradiculopathy is characterized by asymmetric leg weakness involving proximal and distal muscles, flaccid paraparesis, hypo- or areflexia, sacral and lower extremity sensory loss, and sphincter disturbances such as urinary retention. The symptoms develop over a period of 1 to 6 weeks. The finding of “saddle” anesthesia, urinary retention, and a sensory level should raise suspicion for polyradiculopathy, rather than another process such as chronic inflammatory demyelinating polyneuropathy. In herpes zoster radiculitis, pain typically precedes a rash, which develops in a dermatomal distribution in the face or trunk. Motor involvement and weakness can also occur in more severe cases (146).

Cytomegalovirus infection has been identified as a cause of polyradiculopathy. It occurs in approximately 2% of patients with a CD4 cell count of 50 cells/µL or less (51). The patient typically presents with radiating, low back pain, progressive areflexic paraparesis, and distal sensory loss. Two thirds of patients complain of urinary difficulties, including hesitancy or retention (24). Weakness is typically more prominent than sensory loss (150). Cerebrospinal fluid evaluation may reveal polymorphonuclear pleocytosis, hypoglycorrhachia, and a raised protein concentration. Polymerase chain reaction of the cytomegalovirus DNA is positive in approximately 90% of affected patients (42). MRI of the lumbosacral spine may reveal thickened, enhanced nerve roots in approximately one third of patients (12; 217; 117). The classical electrophysiologic profile includes denervation of lower extremity and paraspinal muscles, with normal nerve conduction velocities and sensory potentials (15). However, a coexisting HIV neuropathy causing abnormal sensory potentials could cause confusion.

Anticytomegalovirus therapy with ganciclovir, foscarnet, or a combination of both drugs is imperative because of the rapid progression. In one study of patients with AIDS and acute lumbosacral polyradiculopathy, 15 of 23 patients had cytomegalovirus infection, and treatment with ganciclovir was followed by stabilization (213). Oral acyclovir is usually effective in herpes zoster radiculitis (191).

Radiculopathy has also been associated with syphilis (126), lymphoma (129; 74), vasculitis (163), toxoplasmosis (108), tuberculosis (18), primary CNS lymphoma with lymphomatous meningitis (120), and herpes zoster (53). Also, some data suggest that HIV itself may lead to lumbosacral radiculopathy (213).

Plexopathy. Bilateral brachial neuritis has been described at the time of seroconversion, occurring within 1 to 2 weeks of the acute febrile illness, with pain, weakness, scapular winging, and muscle atrophy (131; 29; 25).

Mononeuropathies. The most common cranial mononeuropathy is facial nerve palsy, with less frequent involvement of cranial nerves II, V, and VIII (131; 159; 86). Bilateral facial nerve palsies have also been reported with HIV infection (231; 198), most commonly occurring at the time of seroconversion, but also with advanced disease (13; 156), possibly secondary to opportunistic infection or lymphoma (190). Herpes zoster, neurosyphilis, and hepatitis C have been associated with facial nerve palsies and should be excluded.

Other mononeuropathies, such as neuropathy of the laryngeal recurrent nerve (134) and bilateral phrenic nerves (170) have been reported in HIV-infected patients. These neuropathies may occur as isolated events or may precede the development of multiple mononeuropathies, ie, mononeuropathy multiplex.

Mononeuritis multiplex. The clinical pattern of mononeuritis multiplex is that of the simultaneous or sequential involvement of individual major peripheral nerves in different limbs, resulting in the often abrupt onset of symptoms in variable distributions. This syndrome may develop early or late in the course of HIV infection (211). Several underlying etiologies of this syndrome should be recognized and include vasculitis, cryoglobulinemia, lymphoma, or cytomegalovirus infection.

Mononeuritis multiplex as a manifestation of polyarteritis nodosa, a vasculitis of medium-sized vessels, may occur at any stage of HIV infection. Though vasculitis classically presents as a mononeuritis multiplex, many patients present with an overlapping symmetrical sensorimotor polyneuropathy, or even a distal sensorimotor polyneuropathy, due to the cumulative involvement (20). The neuropathy symptoms may be accompanied by weight loss, myalgias, and leg tenderness (125; 189; 78). Systemic manifestations, though less frequent, include renal failure, skin rash, testicular pain, arthritis, or hypertension. The erythrocyte sedimentation rate is usually elevated, and patients may be positive for hepatitis B surface antigen (125; 74). Mononeuritis multiplex may also occur in association with an unspecified vasculitis (78), involving small vessels with neutrophilic inflammatory vascular disease. A milder form is associated with a pathological picture of perivasculitis in which there are perivascular inflammatory cells but no vasonecrosis or fibrosis (132), with the neuropathy following a more benign course. Cryoglobulinemia, frequently associated with hepatitis B and C, may cause vasculitis, resulting in mononeuritis multiplex in patients with HIV (123; 125; 10; 214; 130). Invasion of the nerves by lymphoma or Kaposi sarcoma can also result in the clinical picture of mononeuritis multiplex (131; 82; 74). In HIV-infected patients who present with mononeuritis multiplex, the possibility of leprosy should also be suspected, particularly in leprosy endemic areas (77).

A subset of HIV-infected patients develops a hyperimmune response to HIV infection by developing an oligoclonal expansion of CD8+ lymphocytes. Diffuse infiltrative lymphocytosis syndrome may develop due to diffuse visceral lymphocytic infiltration, particularly of the salivary glands and lungs (100; 101; 102; 73). A sensorimotor polyneuropathy may develop due to angiocentric infiltration by CD8 cells and vascular mural necrosis (79). In a series of 12 patients with diffuse infiltrative lymphocytosis syndrome and peripheral neuropathy, all had a sicca syndrome and multivisceral involvement. Four had an asymmetrical and eight a symmetrical neuropathy. Nerve biopsy showed marked angiocentric CD8 infiltrates without mural necrosis and with abundant HIV p24 protein in macrophages. Improvement with AZT was seen in six of six patients, and steroids were beneficial in four of five patients. Two patients developed a primary B cell lymphoma (155).

In later stages of HIV infection when patients have less than 50 CD4 cells, cytomegalovirus may result in a rapidly progressive multifocal neuropathy. This may be confirmed by demonstration of cytomegalovirus in the CSF by polymerase chain reaction accompanied by an elevated protein level and predominantly polymorphonuclear pleocytosis. Characteristic nerve biopsy findings include multiple foci of endoneurial necrosis, inflammatory infiltrates of mononuclear and polymorphonuclear cells, and cytomegalovirus inclusions in endothelial cells of endoneurial capillaries with surrounding inflammation (188; 184). Treatment includes antivirals, such as ganciclovir, foscarnet, and cidofovir, along with immune reconstitution with HAART (180).

Distal polyneuropathy. A predominantly sensory, distal symmetric polyneuropathy is the most common peripheral manifestation seen in HIV-1 infection and typically has been reported to occur in later stages of the disease. Advancing age and treatment with nucleoside analogue reverse transcriptase class of drugs are significant predictors of distal sensory neuropathy (154; 158; 105). These comorbidities include vitamin B12 deficiency, substance abuse (137), medications, and diabetes (71; 143). Hepatitis C co-infection is reportedly not associated with an increased risk of developing sensory neuropathy (35).

Older age, lower CD4 nadir, current combination antiretroviral therapy use, and prior “d-drug” therapy are significant risk factors for developing HIV sensory neuropathy (65; 158).

Patients present with paresthesias typically distal to the ankles. Deep tendon reflexes at the ankles are depressed or absent, and intrinsic foot muscle weakness may be seen in 37% of patients (43). Sensory loss and spontaneous pain are frequently reported (65). Physical examination shows decreased distal vibratory and temperature sensation with increased or decreased sensitivity to pinprick in the toes. Strength and proprioception are generally preserved (180).

Electrophysiologic findings are largely axonal, although demyelinating features have been described to a lesser degree (08; 212). Needle electromyography abnormalities are not typical, but chronic reinnervation changes may be seen (180). Pathologic features include axonal degeneration of long axons in distal regions in a “dying back” pattern, with reduction of both small and large myelinated fiber densities (43; 84; 06). Small fiber nerve damage may be assessed by skin biopsy with quantification of the epidermal nerve fiber density. A decreased epidermal nerve fiber density is associated with greater pain intensity and higher HIV plasma RNA levels (172).

Qualitative changes (such as focal swellings) may precede development of symptomatic distal symmetric polyneuropathy and decreased epidermal nerve fiber density (94; 61). Occasionally, HIV may be cultured from the CSF of affected individuals (98).

Antiretroviral toxic neuropathy has been a well-described complication of exposure to nucleoside analogues, particularly zalcitabine (ddC), but also didanosine (ddl) and stavudine (d4T) (60; 124; 36), which are collectively known as “d-drugs.” Symptoms typically occur in the first 6 weeks of treatment, and the risk of developing a toxic distal symmetric polyneuropathy from a d-drug is usually maximal in the first 3 months of therapy. Although symptoms may subside with termination of treatment, complete resolution is atypical (158). The toxic effect is dose-dependent and is estimated to occur in 15% to 38% of patients receiving these drugs (16; 46; 186). Although less commonly used in the Western nations, the “d drugs” remain a valuable therapy in the developing world (186). The combination of these drugs with hydroxyurea is associated with an increased risk of sensory neuropathy, suggesting a possible synergistic effect between the drugs (153). Now the incidence of peripheral neuropathy is expected to lower as stavudine and didanosine are no longer recommended (119). A study noted that in Sub-Saharan Africa the most common reason for antiretroviral drug regimen change was peripheral neuropathy (17).

The clinical presentation often resembles distal sensory polyneuropathy, with predominantly axonal, sensory electrophysiologic findings. Antiretroviral toxic neuropathy may sometimes be distinguished from distal sensory polyneuropathy by its more painful character, abrupt onset with initiation, and eventual amelioration following cessation of the medication (14; 16; 153). There may also be a “coasting phenomenon” in which the symptoms intensify 2 to 4 weeks following withdrawal of the drug. HIV-infected diabetic patients have poorer blood sugar control and a higher incidence of neuropathy and nephropathy (when defined by overt proteinuria) (171).

Up to 90% of those with HIV-associated sensory neuropathy experience pain and have an adverse effect on quality of life (161). The intensity of distal neuropathic pain is not fully explained by the degree of peripheral nerve damage. Presence of early paresthesias significantly predicts disabling neuropathic pain later in life among older people with HIV having distal sensory polyneuropathy (57). A central mechanism has been suggested. The posterior cingulate is thought to be involved in inhibiting the perception of painful stimuli. It has been demonstrated that smaller posterior cingulate cortex structure may be related to reduced antinociception, leading to increased perception of distal neuropathic pain (109). In a study, Keltner and coworkers noted that smaller midbrain and thalamus were associated with paresthesia alone, but small posterior cingulate cortex was associated with both pain and paresthesia both (110). Abnormalities in calcium/calmodulin-dependent protein kinase (CAMKK2) gene predispose HIV-associated distal sensory peripheral neuropathy (187). A diffusion tensor imaging study using tractography and connectometry noted that severe HIV neuropathy was associated with lower white matter integrity extending from midbrain to somatosensory cortex. This phenomenon suggests an ascending deafferentation extending from damaged peripheral nerves up to third-order neurons (219). Ellis and co-workers observed that declining neurocognitive performance in persons with HIV infection was associated with worsened neuropathic pain. This phenomenon indicated that central pain processing mechanisms do contribute to pathogenesis of neuropathic pain in patients with HIV-associated distal polyneuropathy (66).

Neurotoxicity of antiretroviral drugs is associated with mitochondrial dysfunction via the inhibition of gamma-DNA polymerase, leading to depletion of the nerve’s mitochondrial DNA (46). Pathologic studies have revealed prominent mitochondrial disruption and abnormalities of the cristae (33; 165). Neuropathy and acquired lipodystrophy may be manifestations of these mitochondrial effects (27).

The protease inhibitor indinavir was found to be toxic to HIV-infected dorsal root ganglion cultures (167). However, analysis of 1159 HIV-infected individuals enrolled in a large, prospective, observational multicenter study revealed no statistically significant association when adjustments were made for well-known concomitant risk factors (eg, older age, more advanced disease, greater exposure to neurotoxic d-drugs) (64).

Other medications used in the treatment of AIDS-related complications may also lead to polyneuropathy. Vincristine, a vinca alkaloid used in the treatment of solid tumors, such as Kaposi sarcoma, lymphoma, and leukemia, binds with tubulin and is believed to cause a distal axonopathy by affecting axonal transport (220). Isoniazid for the treatment of tuberculosis and dapsone for the treatment of pneumocystis carinii pneumonia or toxoplasmosis may also cause neuropathy. The antifungal and antibacterial agent metronidazole may produce sensory neuropathy (83). Other potentially neurotoxic medications include chloramphenicol, ethambutol, etoposide, pyridoxine, and thalidomide (180).

Inflammatory demyelinating polyneuropathy. HIV is also associated with acute or chronic inflammatory demyelinating polyneuropathies. These are characterized by weakness, absent deep tendon reflexes, elevated CSF protein, and improvement either spontaneously or due to immunomodulation (44; 176).

Acute inflammatory demyelinating polyneuropathies or Guillain-Barré syndrome may have a bimodal pattern of occurrence, developing at the time of seroconversion and prior to the appearance of HIV antibodies (87; 169; 227; 21; 230) or during the chronic phase of HIV infection (09). Acute inflammatory demyelinating polyneuropathy has also been reported to occur as a complication of immune reconstitution (141; 218).

Electrodiagnostic findings consistent with a primary demyelinating neuropathy (such as severe conduction velocity slowing, prolonged distal latencies, and conduction block) are typical; however, other acute inflammatory demyelinating polyneuropathy variants, such as a motor axonal variant, have been reported (230). CSF pleocytosis in a patient with Guillain-Barre syndrome raises the possibility of HIV infection; however, it is frequently not seen (21). Cytomegalovirus inclusions in Schwann cells have also been found (62; 49).

First line therapy is plasmapheresis or intravenous immunoglobulin (IVIg) as it is in HIV-negative patients with AIDP (178).

There have been reports of patients presenting with a syndrome of rapidly progressive weakness, simulating Guillain-Barre syndrome, typically in the setting of lactic acidosis or symptomatic lactatemia. This is presumed to result from mitochondrial toxicity of nucleoside analogue therapy, particularly D4T, causing eventual disruption of the electron transport chain (233; 183; 204; 31). The electrodiagnostic features are primarily axonal, and most patients have not responded to intravenous immunoglobulin or plasmapheresis (144). The Miller Fisher variant (ophthalmoplegia, ataxia, and areflexia) of Guillain-Barre syndrome has also been described in a patient receiving D4T therapy (199).

These patients may be at increased risk of developing CIDP (21). CIDP tends to develop during the early stages of HIV infection, although it may occur in the setting of AIDS (149; 173; 21). The CSF studies may reveal pleocytosis and the presence of viral antigens. Inflammatory infiltrates, sometimes seen in sural nerve biopsies, consist of CD8+ lymphocytes and macrophages, some of which harbor HIV antigens (47).

Autonomic neuropathy. Autonomic neuropathy becomes clinically relevant in advanced stages of HIV disease (185), generally occurring in conjunction with distal sensory polyneuropathy. Presenting symptoms typically include postural hypotension or gastroparesis (24). An increased incidence of papillary abnormalities (81) and denervation in the jejunal mucosa (11) has been reported. Increased abnormalities by cardiovascular tests, such as prolongation of the QT interval (229), may place the patients at risk during invasive procedures (45; 228). The HIV-associated adipose redistribution syndrome has also been attributed to the adverse effects of antiretroviral drugs on autonomic neurons in the CNS that project to visceral or subcutaneous white adipose tissue compartments (72). A study noted that the vagal nerve involvement in HIV-associated autonomic neuropathy is associated with immune and gastrointestinal function changes in treated HIV patients (179).

Amyotrophic lateral sclerosis (ALS)-like motor neuropathy. Amyotrophic lateral sclerosis (ALS) is a progressive disease resulting from upper and lower motor neuron degeneration. A small percentage of HIV-infected persons develop ALS-like syndrome. Neurologic manifestations in HIV-infected ALS patients resemble classical ALS. It occurs at a younger age and shows a dramatic improvement with antiretroviral therapy (04).

Prognosis and complications

The staging of the HIV infection (determined by the total CD4+ lymphocyte cell count, the total HIV viral load, and the patient’s clinical condition) is a determinant factor in the particular peripheral nerve complication that will occur. The staging also will affect the prognosis.

Clinical vignette

A 40-year-old man with HIV infection for 4 years complained of symmetrical pain in the soles of both feet. The pain was hard, sharp, and achy and had progressed over the past 3 and a half months. The pain was worse at night, and he reported hypersensitivity to touch with bedsheets or shoes. His symptoms began 1 month after starting the medication didanosine. Didanosine was replaced with stavudine; however, the symptoms persisted. He denied weakness or hand symptoms. He denied a history of alcohol or intravenous drug use, though he formerly used crack cocaine.

On neurologic examination, his mental status and cranial nerve functions were normal. His motor strength was normal without atrophy or fasciculations. Deep tendon reflexes were absent at the ankles. He had decreased sensation to vibration and pinprick in the legs distally. His gait was steady.

His CD4 count was 483, and his viral load was less than 200. The following lab studies were normal: hepatitis B and C antibody levels, BUN, creatinine, random glucose, vitamin B12 level, RPR, TSH, serum protein electrophoresis, and antisulfatide antibodies.

Amitriptyline, 75 mg at night, provided mild relief. Gabapentin, 600 mg three times daily, provided no benefit.

Five and a half months after the onset of his symptoms, stavudine was discontinued, and his antiretroviral regimen was changed to abacavir, efavirenz, and lamivudine. After 1 month, his pain improved briefly before worsening. He increased his gabapentin to 1200 mg three times daily, without any noticeable benefit. He had no improvement with zonisamide, 600 mg daily. Lamotrigine was begun at 25 mg per day, and a rash and gastrointestinal upset occurred. He was referred to a pain specialist.

Biological basis

Etiology and pathogenesis

The etiology of the various peripheral nerve disorders is usually due to opportunistic infections, neoplasms, medication toxicity, or possibly secondary to invasion and destruction by HIV itself. (See Clinical Manifestations section for further details.)

The mechanisms behind peripheral nerve complications of HIV have not been fully elucidated. Resulting disease is probably a multifactorial process with current data implicating: (1) toxicity due to macrophages, cytokines, antibodies, viral proteins, mitochondrial dysfunction, or oxidative damage; (2) direct infection; (3) nutritional deficiencies.

Toxicity due to macrophages and cytokines. HIV viral transcripts and antigens have been detected in perivascular and endoneurial macrophages (68; 234). Activated macrophages may result in the elevated production of destructive neural toxins (such as tumor necrosis factor, interleukin-1, and interleukin-6) and the depressed production of others (85; 200; 104). High numbers of macrophages expressing MHC class II markers, tumor necrosis factor alpha, interleukin-1, and interleukin-6 were noted in sural nerve specimens from patients with painful sensory neuropathy (85). These macrophages may play a critical role in causing demyelination, allowing activated lymphocytes and macrophages access across the blood-nerve barrier (47). In one study, the dorsal root ganglia of HIV-infected patients were exposed to supernatants from HIV-infected and activated macrophages, resulting in neuronal retraction in the dorsal root ganglion neurons and oxidative stress in the neuronal cell body (89).

Proinflammatory cytokines and other mediators of inflammation have been demonstrated in the dorsal root ganglia of patients with HIV infection (234; 157). TNF-alpha can activate HIV viral production of latently infected neural cells (221; 216) and induce apoptosis in neuroectodermal cells (197). Arachidonic acid, another substance released by activated macrophages, can activate neuronal NMDA receptors, resulting in an influx of calcium ions and stimulation of nitric oxide synthase. Additionally, macrophage-derived factors such as prostaglandin E2 and leukotrienes may sensitize C polymodal nociceptors and contribute to the neuropathic pain and hyperpathia commonly seen in HIV-neuropathy (84).

Some studies have focused on understanding the high rates of HIV sensory neuropathy, even with successful antiretroviral therapy. These studies indicate that neuronal damage is caused by HIV itself and antiretroviral therapy neurotoxicity. This damage involves mitochondrial dysfunction and activation of the innate immune system in peripheral nerves, leading to increased secretion of proinflammatory cytokines. Additionally, the production profile of these cytokines, influenced by allelic polymorphisms in cytokine gene regulatory regions, affects various diseases, including HIV sensory neuropathy (127).

A study in Northern Greece involving 171 people living with HIV, categorized based on the presence or absence of peripheral neuropathy, highlighted the role of cytokine gene polymorphisms in the pathogenesis of HIV sensory neuropathy (162). For instance, carriers of certain genotypes (IL1a-889/rs1800587 TT and IL4-1098/rs2243250 GG) showed a higher risk for developing HIV sensory neuropathy, whereas others (IL2+166/rs2069763 TT) had a lower probability. These findings, though preliminary, suggest potential genetic markers for susceptibility to HIV sensory neuropathy.

Another study explored how HIV-associated autonomic neuropathy contributes to immune hyperresponsiveness. Forty-two adults with well-controlled HIV underwent autonomic testing, resulting in various Composite Autonomic Severity Scores. Analysis of blood-based immune markers and their correlations depicted increased network complexity with greater HIV-associated autonomic neuropathy severity, linking HIV-associated autonomic neuropathy to chronic immune activation in HIV.

A study on HIV sensory neuropathy in Indonesian and South African patients identified polymorphisms in CAMKK2, P2X7R, and P2X4R genes as risk factors (76). Skin biopsies from HIV+ Indonesians, with and without HIV sensory neuropathy, showed different expressions of these proteins, implicating their role in the condition. For example, CaMKK2 was found near nerve fibers in cases of nerve damage/repair, and varying expressions of P2X7R and P2X4R were observed in specific donor groups.

Toxicity due to viral proteins. The HIV-1 viral envelope protein gp120 has been discovered to exert a toxic effect on neurons through activation of the complement cascade (49; 05) or activation of macrophages to secrete neurotoxic factors (133; 80). The latter process may be enhanced by the loss of certain CD4 cells, which normally counteract macrophage activation by elaborating interleukin-4 and interleukin-10 (41; 232; 223). Gp120 has been shown to bind to CXCR4, a chemokine receptor found on neurons and Schwann cells (114) and can directly induce apoptosis or cellular dysfunction (97; 75). Direct epineurial application of gp120 has been implicated in inducing neuropathic pain (96).

Tat, a viral protein released from HIV-infected cells, is known to activate HIV viral expression, modifying several cellular functions with resulting neurotoxicity (139). Tat, through upregulation of inflammatory cytokines, may facilitate entry of the virus into the central nervous system and play a critical role in the progression of neurologic impairment in the course of HIV-associated dementia (175; 174).

Toxicity due to antibodies. There is some evidence that patients with HIV may have antibodies to components of the peripheral nerve, such as IgM antisulfatide (26; 52; 136). A higher incidence of IgG sulfatide antibodies was noted in HIV patients with distal sensory neuropathy versus HIV patients without distal sensory neuropathy (135). HIV-related autoimmunity has been related to the structural homologies between HIV-1 and immune-regulatory molecules and also to components of myelin, both in the CNS (164) and PNS (202).

Moodley and colleagues assessed the frequency of nodal-paranodal antibodies in HIV-infected patients with chronic immune-mediated radiculoneuropathies in 24 HIV-infected patients diagnosed with various forms of immune-mediated radiculoneuropathies, including chronic inflammatory demyelinating polyneuropathy, ventral root radiculopathies, and dorsal root ganglionopathies, with some patients exhibiting combined central and peripheral demyelination (151). The study evaluated IgG antibodies against nodal (neurofascin 186) and paranodal (neurofascin 155, contactin-1, and contactin-associated protein) cell adhesion molecules using a live cell-based assay. Further, the potential pathogenicity of these antibodies was explored by examining their binding to myelinated co-cultures and assessing complement activation as a possible mechanism for myelin injury. The authors observed that three patients (12.7%) tested positive for neurofascin IgG1 antibodies: one patient with ventral root radiculopathies was positive for NF186, and two others with dorsal root ganglionopathies and a mixed sensory-motor demyelinating neuropathy with optic neuritis were positive for NF155. The authors concluded that the frequency of nodal-paranodal antibodies in HIV-infected patients with immune-mediated radiculoneuropathies is similar to those without HIV. However, the pathogenicity of these antibodies, especially at low titers, remains uncertain in the context of HIV.

Mitochondrial dysfunction. Mitochondrial abnormalities in axons and Schwann cells have been described in sensory nerves of patients with zalcitabine (ddC)-induced neuropathy. This dysfunction is attributed to inhibition of gamma-DNA polymerase, the enzyme responsible for mtDNA replication (46). Variations in the mitochondrial genome (138; 34; 30) and cytokine genotype (37) may influence susceptibility to nucleoside reverse transcriptase inhibitor toxicity. Roda and colleagues demonstrated that both the skin intraepidermal nerve fiber density and sural nerve amplitude correlated with the amount of mitochondrial mutation in people with HIV, specifically in those with HIV-associated sensory neuropathy (181).

Oxidative damage. Gp41 may be neurotoxic by a mechanism involving induction of iNOS that has been studied in HIV dementia (02). Similar mechanisms may play a role in HIV neuropathy.

Direct infection. HIV has been shown to infect ganglion neural cells in vitro (121) and in vivo. The blood-nerve barrier is relatively permeable at the site of the dorsal root ganglion, and HIV DNA and RNA sequences have been demonstrated in the dorsal root ganglion neurons and supporting cells of patients with a predominantly sensory peripheral neuropathy (20). Patients without neuropathy at a similar stage of HIV infection did not have evidence of the HIV genome in neurons. HIV viral RNA has also been amplified from sural nerve biopsies (54; 48), and HIV C2V3 envelope sequences have been amplified from peroneal nerve samples obtained from HIV/AIDS patients (104). As described previously, low levels of HIV replication have also been detected in the perivascular or supporting cells in the dorsal root ganglion (234). These findings, though suggestive of a correlation, do not prove that direct HIV infection of neurons results in neuropathy (47; 20). Because of the low level of neurons affected and the inability of techniques, such as immunohistochemistry, to demonstrate production of viral proteins, most investigators have focused on mechanisms other than direct HIV neuronal infection as the cause of neuropathy or HIV dementia.

Coinfection with HTLV-2 has been shown to increase the risk of HIV neuropathy (59; 236).

Nutritional deficiencies. Nutritional deficiencies resulting from anorexia, diarrhea, or malabsorption should be considered. Vitamin B12 deficiency was reported in some studies (92; 116) but not confirmed by others (177; 222; 226). Impaired production of nerve growth factor due to the depletion of CD4+ T-cells has been proposed as a possible mechanism. Acetyl-carnitine deficiency has also been reported in small studies of HIV patients taking dideoxynucleotide drugs (70), and its supplementation was beneficial in a small open-label study (93). (See the Management section for further details.) Plasma carnitine levels were not correlated with severity of neuropathy in larger studies (206).

Central pain processing mechanisms. Central pain processing mechanisms are held responsible in neuropathogenesis of HIV neuropathic pain. A functional magnetic resonance imaging-based study revealed a significant role of increased anterior insula activation in the pathogenesis of HIV neuropathic pain (215).

Gut microbial dysbiosis. Pathogenic changes in the spectrum of gut microbiota is also thought to play a role in the pathogenesis of HIV neuropathic pain. Ellis and co-workers noted that gut dysbiosis, characterized by reductions in diversity and relative increases in the ratios of Blautia and Clostridium to Lachnospira, contribute to pathogenesis of distal neuropathy in persons with HIV infection (63).

Diagnostic workup

A careful history and examination are essential to determine the disease stage and to localize the area of involvement. Electromyography or nerve conduction studies are useful in determining the distribution of nerve involvement and the degree of axonal or demyelinating damage. A lumbar puncture may detect elevated protein levels in AIDP or CIDP (08; 43) and pleocytosis in cytomegalovirus polyradiculopathy or mononeuritis multiplex (184). CSF studies may reveal evidence of HIV itself (98), cytomegalovirus (by polymerase chain reaction) (184), or elevated lactate levels, which suggest lymphoma (82). MRI of the lumbosacral spine is rarely useful; however, enhancement of the cauda equina in cytomegalovirus polyradiculopathy has been described (12; 217).

Skin biopsy of the calf and thigh may reveal a reduced intraepidermal nerve fiber density in patients with polyneuropathy (172) and has been used to follow the response to potentially therapeutic agents such as nerve growth factor (147; 195). Epidermal nerve fiber density assessment may have a role as a predictor of the development of symptomatic HIV neuropathy (94; 95) and may correlate with the clinical and electrophysiologic severity of the neuropathy (237). One study has shown that HIV+ individuals (including those without neuropathy symptoms) have an impaired capacity to regenerate these small nerve fibers (90).

Sural nerve biopsy is typically performed if the diagnosis remains unknown or if vasculitis, cytomegalovirus or lymphoma is suspected. The array of pathologic findings includes axonal loss, segmental demyelination and perivascular mononuclear cell infiltrates with complement or immunoglobulin deposition. The inflammatory cells usually are macrophages or T-lymphocytes, predominantly of the CD8+ cytotoxic or suppressor cell type.

Management

Supportive measures are discussed in Peripheral neuropathies: supportive measures and rehabilitation.

The primary management goal is control of the underlying process with HAART.

Nerve growth factor, an important neurotrophin that modulates the activity of small sensory nerve fibers, was investigated as a potential target for intervention in distal sensory polyneuropathy. Nerve growth factor was safe and well-tolerated and significantly improved pain symptoms; however, there was no improvement of neuropathy severity as assessed by neurologic examination, quantitative sensory testing, and epidermal nerve fiber density (195).

The management of demyelinating neuropathies, including AIDP and CIDP, is the same as for non-HIV-1 infected patients. Both conditions respond to plasmapheresis (43; 118) or IVIg (40; 142). There is one case report of a patient who developed acute inflammatory demyelinating polyneuropathies during the chronic phase of HIV infection, who had dramatic resolution of the neuropathy following HAART therapy alone (09). Mononeuropathies in HIV-infected patients, particularly recurrent laryngeal and bilateral phrenic neuropathies, have been reported to respond to high-dose IVIg (134; 170). Corticosteroids may be beneficial in patients with a painful distal sensory polyneuropathy due to vasculitis (19). It should be mandatory that all patients receiving isoniazid receive pyridoxine to prevent isoniazid-associated neuropathy (119).

Treatment of neuropathic pain symptoms remains a challenge (21), with many medications showing little or no superiority to placebo. Typical agents include anticonvulsants, antidepressants, topical agents, and opioids.

Anticonvulsants. Gabapentin has been reported to be helpful (160; 88); however, a randomized clinical trial did not demonstrate superiority to placebo (88; 168). Nonetheless, it is a desirable treatment given the decreased incidence of drug-to-drug interactions (182). A typical starting dose is 100 mg three times daily, with subsequent escalation up to as much as 3600 mg/day as tolerated.

Pregabalin is a GABA analogue that acts on the alpha-2-delta ligand of voltage-activated calcium channels. It is an FDA-approved treatment for diabetic neuropathy, postherpetic neuralgia, fibromyalgia, and partial seizures. A placebo-controlled trial, however, showed that pregabalin was well tolerated but no better than placebo for treatment of the painful symptoms of HIV neuropathy (209). A Cochrane review failed to demonstrate efficacy of pregabalin in HIV neuropathy (55).

Lamotrigine has been proven in placebo-controlled trials to be effective for HIV-associated painful sensory neuropathies (208; 207). Patients not receiving drugs known to induce the metabolism of lamotrigine started at a dose of 25 mg every other day for the first 2 weeks, with a target maintenance dose of 600 mg/day (300 mg twice daily). Patients who were receiving drugs known to induce the metabolism of lamotrigine started at a dose of 25 mg daily, with a target maintenance dose of 400 mg/day (200 mg twice daily).

Anticonvulsants, such as phenytoin and carbamazepine, which are highly protein-bound or induce cytochrome P450, should be avoided as they might affect the efficacy of protease inhibitors (182). Valproate should also be used cautiously as it has been shown in vitro to stimulate HIV (152) and cytomegalovirus replication (122).

Antidepressants. Tricyclic antidepressants and selective serotonin-norepinephrine reuptake inhibitors (SNRIs) are the two major classes used in the treatment of neuropathic pain. Controlled studies of amitriptyline, mexiletine, memantine, and acupuncture have been negative (111; 115; 201; 196). Duloxetine is an SNRI that is an FDA-approved treatment for diabetic neuropathy. A typical starting dose is 30 mg daily, with slow titration up to a maximum of 120 mg daily. It is also being studied for HIV-related neuropathy. In one randomized trial, amitriptyline was found ineffective in painful HIV-associated sensory neuropathy (58).

Topical treatments. Capsaicin, the active component of chili peppers, is known to bind to the excitatory vanilloid receptor (TRPVR1), which is expressed on small-diameter afferent neurons specialized for the detection of noxious sensations. By activating these receptors, the capsaicin initially produces a burning sensation, and at higher concentrations, desensitizes these nociceptors. Low concentrations are not effective in painful HIV neuropathy; however, a single application of a high-concentration (8%) dermal patch (NGX-4010) was found to provide some benefit (203; 107). This treatment is currently approved by the United States FDA for postherpetic neuralgia only. Topical lidocaine, in gel or patch form, has not been found to be effective (69). High-concentration topical capsaicin can be considered when other forms of drug treatment have failed (56).

Other treatments. Oral acetyl-L-carnitine (1500 mg twice daily) has been demonstrated to result in a reduction in neuropathic pain and a significant increase in cutaneous innervation in one open cohort of 21 HIV-positive patients followed for up to 33 months (93). In another study, pain improvement was noted with 3000 mg of acetyl-L-carnitine daily; however, no change in epidermal fiber density was noted after 24 weeks of therapy (224). In a double-blind, placebo-controlled trial involving patients with ATN, acetyl-L-carnitine (500 mg twice a day intramuscularly for 14 days, followed by 1000 mg twice a day orally for 42 days) was found to result in improved pain ratings versus placebo (235).

Smoked cannabis in a monitored setting was shown to have efficacy in relieving pain in a controlled trial (01). In a randomized, crossover trial, 46% of patients experienced at least 30% pain relief, compared to18% for placebo (67). In this study, cannabis of potency between 1% and 8% tetrahydrocannabinol was smoked four times daily for 5 consecutive days during each of two treatment weeks, separated by a 2-week washout period. Medical marijuana is a potentially effective therapy for HIV-associated sensory neuropathy, and its controlled use may be recommended in future (128).

Randomized controlled trials of subcutaneous recombinant human nerve growth factor (rhNGF) showed that it was superior to placebo for pain relief (147; 168). Studies of newer agents, such as subcutaneous prosaptide and intranasal peptide T, were negative (168).

Opioids have not been formally studied in painful HIV-related sensory neuropathy (168); however, they may be useful for moderate to severe neuropathic pain. Careful patient selection and screening for substance abuse is imperative.

Hypnosis has shown efficacy in clinical trials but due to limited access is not typically used in the clinical setting. Acupuncture has not been shown to be effective (180).

Management of autonomic symptoms focuses on removing exacerbating factors, such as drugs, which might cause orthostatic hypotension or anticholinergic side effects. If salt supplementation and compressive stockings are ineffective for treating orthostatic hypotension, fludrocortisone may be tried. Promotility drugs such as cisapride may be used to treat gastroparesis. Sildenafil can help those with erectile dysfunction (24).

The immunophilin ligand, FK506, was found to have a neuroprotective effect in an in vitro model of toxic neuropathy due to ddC. Some studies have indicated that neuroprotection is via inhibition of calcineurin, a calcium-dependent protein phosphatase (112). The hematopoietic growth factor, erythropoietin, has also been shown to prevent sensory axonal degeneration and in vitro dorsal root ganglion neuronal death by both the HIV envelope protein gp120 and zalcitabine (ddC) (113).

Outcomes

With the advent of HAART, the incidence of some complications (eg, HIV-related lumbosacral radiculopathy, cytomegalovirus polyradiculopathy, cytomegalovirus-induced mononeuritis multiplex, medication-related neuropathy [antiretroviral drugs], and autonomic neuropathy) has diminished, whereas there has been an increase in the incidence of peripheral neuropathy, both distal sensory polyneuropathy and antiretroviral toxic neuropathy.

A multinational study demonstrated that there was substantial reduction in the prevalence of distal sensory peripheral neuropathy following combination antiretroviral treatment in treatment-naive people living with HIV. Before initiating combination antiretroviral treatment, 21.3% of people living with HIV had distal sensory peripheral neuropathy compared with 8.5% of people not living with HIV. This study also noted that combination antiretroviral treatment-naive patients with HIV with distal sensory peripheral neuropathy were more likely to experience depression and loss of productivity. Overall prevalence of distal sensory peripheral neuropathy among those virally suppressed on combination antiretroviral treatment significantly decreased (225).

References

01: Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy. Neurology 2007;68:515-21. PMID 17296917
02: Adamson DC, McArthur JC, Dawson TM, Dawson VL. Rate and severity of HIV-associated dementia (HAD): correlations with Gp41 and iNOS. Molecular Medicine 1999;5:98-109. PMID 10203575
03: Amiji IA, Naburi HE, Kija E, et al. Peripheral neuropathy in HIV-infected children attending care and treatment clinic, at Muhimbili National Hospital, Dar es Salaam: a cross sectional study. BMC Neurol 2021;21(1):314. PMID 34388988
04: Anand KS, Wadhwa A, Garg J, Mahajan RK. Amyotrophic lateral sclerosis-like presentation in a HIV-positive patient. J Int Assoc Provid AIDS Care 2014;13(6):515-8. PMID 24842949
05: Apostolski S, McAlarney T, Hays AP, Latov N. Complement dependent cytotoxicity of sensory ganglion neurons mediated by the gp120 glycoprotein of HIV-1. Immunological Investigations 1994;23:47-52. PMID 8144198
06: Araujo AP, Nascimento OJ, Garcia OS. Distal sensory polyneuropathy in a cohort of HIV-infected children over five years of age. Pediatrics 2000;106:E35. PMID 10969119
07: Bacellar H, Munoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1 related neurologic disease: multicenter AIDS cohort study, 1985-1992. Neurology 1994;44:1892-900. PMID 7936243
08: Bailey RO, Baltch AL, Venkatesh R, Singh JK, Bishop MB. Sensory motor neuropathy associated with AIDS. Neurology 1988;38:886-91. PMID 2835708
09: Bani-Sadr F, Neuville S, Crassard I, Guihot A, Molina JM. Acute Guillain-Barré syndrome during the chronic phase of HIV infection and dramatic improvement under highly active antiretroviral therapy. AIDS 2002;16:1562. PMID 12131198
10: Bardin T, Gaudouen, Kuntz D, et al. Necrotizing vasculitis in human immunodeficiency virus infection. Arthritis Rheum 1989;30(suppl 4):S105.
11: Batman PA, Miller AR, Sedgwick PM, Griffin GE. Autonomic denervation in jejunal mucosa of homosexual men infected with HIV. AIDS 1991;5:1247-52. PMID 1786151
12: Bazan C 3rd, Jackson C, Jinkins JR, Barohn RJ. Gadolinium-enhanced MRI in a case of cytomegalovirus polyradiculopathy. Neurology 1991;41:1522-3. PMID 1653916
13: Belec L, Georges AJ, Vuillecard E, Galin M, Martin PM. Peripheral facial paralysis indicating HIV infection. Lancet 1988;2(8625):1421-2. PMID 2904544
14: Berger AR, Arezzo JC, Schaumburg HH, et al. 2’,3’-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 1993;43:358-62. PMID 8382349
15: Beydoun SR. Misdiagnosis of cytomegalovirus polyradiculopathy, coexisting with HIV neuropathy. Muscle Nerve 1991;14(6):575-6. PMID 1649399
16: Blum AS, Dal Pan GJ, Feinberg J, et al. Low-dose zalcitabine-related toxic neuropathy: frequency, natural history, and risk factors. Neurology 1996;46:999-1003. PMID 8780079
17: Bokore A, Korme B, Bayisa G. Determinants of anti-retroviral regimen changes among HIV/AIDS patients of east and west Wollega zone health institutions, Oromia region, west Ethiopia: a cross-sectional study. BMC Pharmacol Toxicol 2018;19(1):28. PMID 29871665
18: Botzel K. Tuberkulöse Radikulomyelitis-gut therapierbar nur bei frühem Erkennen. Der Nervenar 1993;64:282-3.
19: Bradley WG, Verma A. Painful vasculitic neuropathy in HIV-1 infection: relief of pain with prednisone therapy. Neurology 1996;47(6):1446-51. PMID 8960725
20: Brannagan TH 3rd. Retroviral-associated vasculitis of the nervous system. Neurol Clin 1997;15:927-944. PMID 9367973
21: Brannagan TH 3rd. Peripheral neuropathy pain: mechanisms and treatment. J Clin Neuromusc Dis 2003;5:61-71. PMID 19078723
22: Brannagan TH 3rd, Nuovo GJ, Hays AP, Latov N. Human immunodeficiency virus infection of dorsal root ganglion neurons detected by polymerase chain reaction in situ hybridization. Ann Neurol 1997;42:368-72. PMID 9307260
23: Brannagan TH 3rd, Zhou Y. HIV-associated Guillain-Barré syndrome. J Neurol Sci 2003;208:39-42. PMID 12639723
24: Brew BJ. The peripheral nerve complications of human immunodeficiency virus (HIV) infection. Muscle Nerve 2003;28:542-52. PMID 14571455
25: Brew BJ, Perdiceds M, Darveniza P, et al. The neurological features of early and “latent” human immunodeficiency virus. Aust NZ J Med 1989;19:700-5. PMID 2631662
26: Briani C, Dalakas M, Zakir R, et al. AIDS Neuropathy: presence of autoantibodies to peripheral nerve antigens. (Abstract) Neurology 1996;46(supplement):A236.
27: Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-5. PMID 10509516
28: Britton CB, Marruardt MD, Koppel B, et al. Neurological complications of the gay immunosuppressed syndrome: clinical and pathological features. Ann Neurol 1982;12:80.
29: Calabrese LH, Proffitt MR, Levin KH, Yen-Lieberman B, Starkey C. Acute infection with the human immunodeficiency virus associated with acute brachial neuritis and exanthematous rash. Ann Int Med 1987;107:849-51. PMID 3688679
30: Canter JA, Haas DW, Kallianpur AR, et al. The mitochondrial pharmacogenomics of haplogroup T: MTND2LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenomics J 2008;8(1):71-7. PMID 17684475
31: Capers KN, Turnacioglu S, Leshner RT, Crawford JR. Antiretroviral therapy-associated acute motor and sensory axonal neuropathy. Case Rep Neurol 2011;3:1-6. PMID 21327178
32: Chavanet P, Solary E, Giroud M, et al. Infraclinical neuropathies related to immunodeficiency virus infection associated with higher T-helper cell count. J Acq Immune Def Synd 1989;2:564-9. PMID 2555472
33: Chen CH, Vazquez-Padua M, Cheng YC. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991;39:625-8. PMID 1851960
34: Chen X, Goudsmit J, Van Der Kuyl A. Lack of correlation between length variation in the DNA polymerase gamma gene CAG repeat and lactic acidosis or neuropathy during antiretroviral treatment. AIDS Res Hum Retroviruses 2002;18:531-4. PMID 12036482
35: Cherry CL, Affandi JS, Brew BJ, et al. Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patient with HIV. Neurology 2010;74:1538-42. PMID 20458071
36: Cherry CL, McArthur JC, Hoy JF, Wesselingh SL. Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol 2003;26:195-207. PMID 12600651
37: Cherry CL, Rosenow A, Affandi JS, McArthur JC, Wesselingh SL, Price P. Cytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts an individual’s NRTI-SN risk. AIDS Res Hum Retroviruses 2008;24(2):117-23. PMID 18240960
38: Cherry CL, Skolasky RL, Lal L, et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology 2006;66:867-73. PMID 16567704
39: Childs EA, Lyles RH, Selnes OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999;52:607-13. PMID 10025796
40: Chimowitz MI, Audet AM, Hallet A, Kelly JJ Jr. HIV-associated CIDP. Muscle Nerve 1989;12(8):695-6. PMID 2779608
41: Choa CC, Molitor TW, Hu S. Neuroprotective role of IL4 against activated microglia. J Immunol 1993;151:1473. PMID 8335941
42: Cinque P, Scarpellini P, Vago L, Linde A, Lazzarin A. Diagnosis of central nervous system complications in HIV infected patients: CSF analysis by the polymerase chain reaction. AIDS 1997;11:1-17. PMID 9110070
43: Cornblath DR, McArthur JC. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 1988;38:794-6. PMID 2834669
44: Cornblath DR, McArthur JC, Kennedy PG, Witte AS, Griffin JW. Inflammatory demyelinating peripheral neuropathies associated with human T-cell lymphotropic virus type III infection. Ann Neurol 1987;21:32040. PMID 3030188
45: Craddock C, Pasvol G, Bull R, Protheroe A, Hopkin J. Cardiorespiratory arrest and autonomic neuropathy in AIDS. Lancet 1987;2:16-8. PMID 2885506
46: Dalakas MC. Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 2001;6:14-20. PMID 11293802
47: Dalakas MC, Cupler EJ. Neuropathies in HIV infection. Baillieres Clin Neurol 1996;5:199-218. PMID 8732208
48: Dalakas MC, Illa I, Monzon M. Retrovirus-related neuromuscular diseases. In: Hohlfeld R, editor. Immunology of Neuromuscular Disease. Boston: Kluwer Academic Publishing, 1994:256-88.
49: Dalakas MC, Pezeshkpour GH. Neuromuscular diseases associated with human immunodeficiency virus infection. Ann Neurol 1988;23(suppl):S38-48. PMID 2831801
50: Dalakas MC, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2’,3’-dideoxycytidine (ddC). Lab Invest 2001;81:1537-44. PMID 11706061
51: de Gans J, Portegies P, Tiessens G, Troost D, Danner SA, Lange JM. Therapy for cytomegalovirus polyradiculopathy in patients with AIDS: treatment with ganciclovir. AIDS 1990;4:421-5. PMID 2164819
52: De Gasperi R, Angel M, Sosa G, et al. Intrathecal synthesis of anti-sulfatide IgG is associated with peripheral nerve disease in acquired immunodeficiency syndrome. AIDS Res Hum Retroviruses 1996;12:205-11. PMID 8835198
53: De La Blanchardiere A, Rozenberg F, Caumes E, et al. Neurological complications of varicella-zoster virus infection in adults with human immunodeficiency virus infection. Scand J Infect Dis 2000;32:263-9. PMID 10879596
54: de la Monte SM, Gabuzda DH, Ho DD, et al. Peripheral neuropathy in the acquired immunodeficiency syndrome. Ann Neurol 1988;23:485-92. PMID 2839106
55: Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev 2019;1:CD007076. PMID 30673120
56: Derry S, Sven-Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2013;(2):CD007393. PMID 23450576
57: Diaz MM, Keltner JR, Simmons AN, et al. Paresthesia predicts increased risk of distal neuropathic pain in older people with HIV-associated sensory polyneuropathy. Pain Med 2021;22(8):1850-6. PMID 33565583
58: Dinat N, Marinda E, Moch S, et al. Randomized, double-blind, crossover trial of amitriptyline for analgesia in painful HIV-associated sensory neuropathy. PLoS One 2015;10(5):e0126297. PMID 25974287
59: Dooneief G, Marlink R, Bell K, et al. Neurologic consequences of HTLV-II infection in injection-drug users. Neurology 1996;46:1556-60. PMID 8649548
60: Dubinsky RM, Yarchoan R, Dalakas M, Broder S. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2’,3’-dideoxycytidine (ddC). Muscle Nerve 1989;12:856-60. PMID 2558314
61: Ebenezer GJ, McArthur JC, Thomas D, et al. Denervation of skin in neuropathies: the sequence of axonal and Schwann cell changes in skin biopsies. Brain 2007;130(Pt 10):2703-14. PMID 17898011
62: Eidelberg D, Sotrel A, Vogel H, Walker P, Kleefield J, Crumpacker CS 3rd. Progressive polyradiculopathy in acquired immune deficiency syndrome. Neurology 1986;36:912-6. PMID 3012412
63: Ellis RJ, Heaton RK, Gianella S, et al. Reduced gut microbiome diversity in people with HIV who have distal neuropathic pain. J Pain 2022a;23(2):318-25. PMID 34530155
64: Ellis RJ, Marquie-Beck J, Delaney P, et al. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol 2008;64(5):566-72. PMID 19067367
65: Ellis RJ, Rosario D, Clifford DB, et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy. Arch Neurol 2010;67(5):552-8. PMID 20457954
66: Ellis RJ, Sacktor N, Clifford DB, et al. Neuropathic pain correlates with worsening cognition in people with human immunodeficiency virus. Brain 2022b;145(6):2206-13. PMID 35773234
67: Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009;34(3):672-80. PMID 18688212
68: Esiri MM, Morris CS, Millard PR. Sensory and sympathetic ganglia in HIV-1 infection: immunocytochemical demonstration of HIV-1 viral antigens, increased MHC class II antigen expression and mild reactive inflammation. J Neurol Sci 1993;114(2):178-87. PMID 8445399
69: Estanislao L, Carter K, McArthur J, Olney R, Simpson D; Lidoderm-HIV Neuropathy Group. A randomized controlled trial of 5% lidocaine gel for HIV-associated distal symmetric polyneuropathy. J Acquir Immune Defic Syndr 2004;37(5):1584-6. PMID 15577414
70: Famularo G, Moretti S, Marcellini S, et al. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS 1997;11(2):185-90. PMID 9030365
71: Fichtenbaum CJ, Clifford DB, Powderly WG. Risk factors for Dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10(2):169-74. PMID 7552481
72: Fliers E, Sauerwein HP, Romijn JA, et al. HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy. Lancet 2003;362:1758-60. PMID 14643128
73: Franco-Paredes C, Rebolledo P, Folch E, Hernandez I, del Rio C. Diagnosis of diffuse CD8+ lymphocytosis syndrome in HIV-infected patients. AIDS Read 2002;12(9):408-13. PMID 12402804
74: Fuller GN, Jacobs JM, Guiloff RJ. Nature and incidence of peripheral nerve syndromes in HIV infection. J Neurol Neurosurg Psychiatry 1993;56:372-81. PMID 8387098
75: Gabuzda D, Wang J. Chemokine receptors and mechanisms of cell death in HIV neuropathogenesis. J Neurovirol 2000;6(Suppl 1):S24-32. PMID 10871762
76: Gaff J, Octaviana F, Jackaman C, et al. Expression in skin biopsies supports genetic evidence linking CAMKK2, P2X7R and P2X4R with HIV-associated sensory neuropathy. J Neurovirol 2023;29(3):241-51. PMID 37166584
77: Galtrey CM, Modarres H, Jaunmuktane Z, et al. Leprosy in a patient infected with HIV. Pract Neurol 2017;17(2):135-9. PMID 27941127
78: Gherardi R, Belec L, Mhiri C, et al. The spectrum of vasculitis in human immunodeficiency virus-infected patients. Arthritis Rheum 1993;36:1164-74. PMID 8343192
79: Gherardi RK, Chretien F, Delfau-Larue MH, et al. Neuropathy in diffuse infiltrative lymphocytosis syndrome: an HIV neuropathy, not a lymphoma. Neurology 1998;50:1041-4. PMID 9566392
80: Giulian D, Wendt E, Vaca K, Noonan CA. The envelope glycoprotein of human immunodeficiency virus type 1 stimulates release of neurotoxins from monocytes. Proc Natl Acad Sci USA 1993;90(7):2769-73. PMID 8464887
81: Gluck T, Degenhardt E, Scholmerich J, Lang B, Grossmann J, Straub RH. Autonomic neuropathy in patients with HIV: course, impact of disease stage, and medication. Clin Auton Res 2000;10:17-22. PMID 10750639
82: Gold JE, Jimenez E, Zalusky R. Human immunodeficiency virus-related lymphoreticular malignancies and peripheral neurologic disease. Cancer 1988;61:2318-24. PMID 3365659
83: Gondim FA, Brannagan TH 3rd, Sander HW, Chin RL, Latov N. Peripheral neuropathy in patients with inflammatory bowel disease. Brain 2005;128(Pt 4):867-79. PMID 15705608
84: Griffin JW, Crawford TO, McArthur JC. Peripheral neuropathies associated with HIV infection. In: Gendelman HE, Lipton SA, Epstein L, Swindels S, editors. The Neurology of AIDS. New York: Chapman and Hall, 1998:275-91.
85: Griffin JW, Wesselingh SL, Griffin DE, et al. Peripheral nerve disorders in HIV infection. In: Price RW, Perry SW, editors. HIV, AIDS, and the Brain. New York: Raven Press, 1994:159-82.
86: Grimaldi LM, Luzi L, Martino GV, et al. Bilateral eighth cranial nerve neuropathy in human immunodeficiency virus infection. J Neurol 1993;240:363-6. PMID 8336177
87: Hagberg L, Malmvall BE, Svennerholm L, Alestig K, Norkrans G. Guillain-Barré syndrome as an early manifestation of HIV central nervous system infection. Scand J Infect Dis 1986;18:591-2. PMID 3468607
88: Hahn K, Arendt G, Braun JS, et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 2004;251:1260-6. PMID 15503108
89: Hahn K, Robinson B, Anderson C, et al. Differential effects of HIV infected macrophages on dorsal root ganglia neurons and axons. Exp Neurol 2008;210(1):30-40. PMID 18177640
90: Hahn K, Triolo A, Hauer P, et al. Impaired reinnervation in HIV infection following experimental denervation. Neurology 2007;68:1251-56. PMID 17438214
91: Hall CD, Snyder CR, Messenheimer JA, et al. Peripheral neuropathy in a cohort of human immunodeficiency virus-infected patients. Incidence and relationship to other nervous system dysfunction. Arch Neurol 1991;48:1273-4. PMID 1668978
92: Harriman GR, Smith PD, Horne MK, et al. Vitamin B12 malabsorption in patients with acquired immunodeficiency syndrome. Arch Intern Med 1989;149:2039-41. PMID 2774781
93: Hart AM, Wilson AD, Montovani C, et al. Acetyl-L-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS 2004;18:1549-60. PMID 15238773
94: Herrmann DN, McDermott MP, Henderson D, et al. Epidermal nerve fiber density, axonal swellings and QST as predictors of HIV distal sensory neuropathy. Muscle Nerve 2004;29:4240-427. PMID 14981742
95: Herrmann DN, McDermott MP, Sowden JE, et al. Is skin biopsy a predictor of transition to symptomatic HIV neuropathy. A longitudinal study. Neurology 2006;66:857-61. PMID 16567702
96: Herzberg U, Sagen J. Peripheral nerve exposure to HIV viral envelope protein gp120 induces neuropathic pain and spinal gliosis. J Neuroimmunol 2001;116:29-39. PMID 11311327
97: Hesselgesser J, Taub D, Baskar P, et al. Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 alpha is mediated by the chemokine receptor CXCR4. Curr Biol 1998;8:595-8. PMID 9601645
98: Hollander H, Levy JA. Neurologic abnormalities and recovery of human immunodeficiency virus from cerebrospinal fluid. Ann Int Med 1987;106:692-5. PMID 3646001
99: Husstedt IW, Grotemeyer KH, Busch H, Zidek W. Progression of distal-symmetric polyneuropathy in HIV infection: a prospective study. AIDS 1993;7:1069-73. PMID 8397942
100: Itescu S, Brancato LJ, Buxbaum J, et al. A diffuse infiltrative CD8 lymphocytosis syndrome in human immunodeficiency virus (HIV) infection: a host immune response associated with HLA-DR5. Ann Int Med 1990;112:3-10. PMID 2136714
101: Itescu S, Dalton J, Zhang HZ, Winchester R. Tissue infiltration in a CD8 lymphocytosis syndrome associated with human immunodeficiency virus-1 infection has the phenotypic appearance of an antigenically driven response. J Clin Invest 1993;91:2216-25. PMID 8486784
102: Itescu S, Winchester R. Diffuse infiltrative lymphocytosis syndrome: A disorder occurring in human immunodeficiency virus-1 infection that may present as a sicca syndrome. Rheum Dis Clin North Am 1992;18:683-97. PMID 1496168
103: Janssen RS, Saykin AJ, Kaplan JE, et al. Neurological complications of human immunodeficiency virus infection in patients with lymphadenopathy syndrome. Ann Neurol 1988;23:49-55. PMID 3345067
104: Jones G, Zhu Y, Silva C, et al. Peripheral nerve-derived HIV-1 is predominantly CCR5-dependent and causes neuronal degeneration and neuroinflammation. Virology 2005;334:178-93. PMID 15780868
105: Julian T, Rekatsina M, Shafique F, et al. Human immunodeficiency virus-related peripheral neuropathy: a systematic review and meta-analysis. Eur J Neurol 2021;28(4):1420-31. PMID 33226721
106: Kallianpur AR, Hulgan T, Canter JA, et al. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS 2006;20:1503-13. PMID 16847405
107: Katz NP, Mou J, Paillard FC, et al. Predictors of response in patients with postherpetic neuralgia and HIV-associated neuropathy treated with the 8% capsaicin patch (Qutenza). Clin J Pain 2015;31(10):859-66. PMID 25503598
108: Kayser C, Campbell R, Sartorious C, Bartlett M. Toxoplasmosis of the conus medullaris in a patient with hemophilia A-associated AIDS. Case report. J Neurosurg 1990;73:951-3. PMID 2230980
109: Keltner JR, Connolly CG, Vaida F, et al. HIV distal neuropathic pain is associated with smaller ventral posterior cingulate cortex. Pain Med 2017;18(3):428-40. PMID 27497320
110: Keltner JR, Tong A, Visser E, et al. Evidence for a novel subcortical mechanism for posterior cingulate cortex atrophy in HIV peripheral neuropathy. J Neurovirol 2020;26(4):530-43. PMID 32524422
111: Kemper CA, Kent G, Burton S, Deresinski SC. Mexiletine for HIV-infected patients with painful peripheral neuropathy: a double-blind, placebo-controlled, crossover treatment trial. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:367-72. PMID 9833745
112: Keswani SC, Chander B, Hasan C, Griffin JW, McArthur JC, Hoke A. FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Ann Neurol 2003a;53:57-64. PMID 12509848
113: Keswani SC, Leitz GJ, Hoke A. Erythropoietin is neuroprotective in models of HIV sensory neuropathy. Neurosci Lett 2004;371:102-5. PMID 15519737
114: Keswani SC, Polley M, Pardo CA, Griffin JW, McArthur JC, Hoke A. Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol 2003b;54:287-96. PMID 12953261
115: Kieburtz K, Simpson D, Yiannoutsos C, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. Neurology 1998;51:1682-8. PMID 9855523
116: Kieburtz KD, Giang DW, Schiffer RB, Vakil N. Abnormal vitamin B12 metabolism in human immunodeficiency virus infection. Association with neurological dysfunction. Arch Neurol 1991;48:312-4. PMID 1848071
117: Kim YS, Hollander H. Polyradiculopathy due to cytomegalovirus: report of two cases in which improvement occurred after prolonged therapy and review of the literature. Clin Infect Dis 1993;17:32-7. PMID 8394748
118: Kiprov D, Pfaeffl W, Parry G, Lippert R, Lang W, Miller R. Antibody-mediated peripheral neuropathies associated with ARC and AIDS: Successful treatment with plasmapheresis. J Clin Apheresis 1988;4:3-7. PMID 3391987
119: Kiwuwa-Muyingo S, Kikaire B, Mambule I, et al. Prevalence, incidence and predictors of peripheral neuropathy in African adults with HIV infection within the DART trial. AIDS 2014;28(17):2579-88. PMID 25574960
120: Klein P, Zientek G, VandenBerg SR, Lothman E. Primary CNS lymphoma: lymphomatous meningitis presenting as a cauda equina lesion in an AIDS patient. Can J Neurol Sci 1990;17:329-31. PMID 2207891
121: Kunsch C, Wigdahl B. Maintenance of human immunodeficiency virus type-1 proviral DNA in human fetal dorsal root ganglia neural cells following a nonproductive infection. J Leuko Biol 1991;49:505-10. PMID 2016571
122: Kuntz-Simon G, Orbert G. Sodium valproate, an anticonvulsant drug, stimulates human cytomegalovirus replication. J Gen Virol 1995;76:151-8. PMID 7782769
123: Lafeuillade A, Aubert L, Detolle P, et al. Dysglobulinémie monoclonale et vascularite systémique nécrosante associées au sida. Sem Hop Paris 1988;64:1477-80.
124: Lambert JS, Seidlin M, Reichman RC, et al. 2’,3’-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: a phase I trial. N Eng J Med 1990;322:1333-40. PMID 2139173
125: Lange DJ, Britton CB, Younger DS, Hays AP. The neuromuscular manifestations of human immunodeficiency virus infections. Arch Neurol 1988;45:1084-8. PMID 2845898
126: Lanska MJ, Lanska DJ, Schmidley JW. Syphilitic polyradiculopathy in an HIV-positive man. Neurology 1988;38:1297-301. PMID 2840606
127: Lawrence S, Mueller BR, Benn EKT, Kim-Schulze S, Kwon P, Robinson-Papp J. Autonomic neuropathy is associated with more densely interconnected cytokine networks in people with HIV. J Neuroimmune Pharmacol 2023;18(4):563-72. PMID 37923971
128: Larriviere DG. Medical marijuana for HIV-associated sensory neuropathy: legal and ethical issues. Continuum (Minneap Minn) 2014;20(5):1426-9. PMID 25299291
129: Leger JM, Henin D, Belec L, et al. Lymphoma-induced polyradiculopathy in AIDS: two cases. J Neurology 1992;239:132-4. PMID 1315382
130: Le Lostec Z, Fegueux S, Vitale C, Geoffroy O, Bleton F, Mornet P. Peripheral neuropathy associated with cryoglobulinaemia but not related to hepatitis C virus in an HIV-infected patient. AIDS 1994;8:1351-2. PMID 7802997
131: Levy RM, Bredesen DE, Rosenblum ML. Neurological manifestations of the acquired immunodeficiency syndrome: experience at UCSF and review of the literature. J Neurosurg 1985;62:475-95. PMID 2983051
132: Lipkin WI, Parry G, Kiprov D, Abrams D. Inflammatory neuropathy in homosexual men with lymphadenopathy. Neurology 1985;35:1479-83. PMID 2993951
133: Lipton SA. Requirement for macrophages in neuronal injury induced by HIV envelope glycoprotein gp 120. Neuroreport 1992;3:913-5. PMID 1421098
134: Loddenkemper T, Evers S, Hahn M, Reichelt D, Husstedt IW. Mononeuropathy of the laryngeal recurrent nerve as possible manifestation of human immunodeficiency virus infection. Otolaryngol Head Neck Surg 2004;131:556-7. PMID 15467635
135: Lopate G, Pestronk A, Evans S, Li L, Clifford D. Anti-sulfatide antibodies in HIV-infected individuals with sensory neuropathy. Neurology 2005;64:1632-4. PMID 15883332
136: Lopate G, Strieft B, Reese R, et al. Anti-sulfatide antibodies in HIV infected patients with neuropathy. J Neurol Sci 2002;199(suppl):P261.
137: Lopez OL, Becker JT, Dew MA, Caldararo R. Risk modifiers for peripheral sensory neuropathy in HIV infection/AIDS. Eur J Neurol 2004;11:97-102. PMID 14748769
138: Luzhansky JZ, Pierce AB, Hoy JF, Hall AJ. Leber’s hereditary optic neuropathy in the setting of nucleoside analogue toxicity. AIDS 2001;15:1588-9. PMID 11504997
139: Magnuson DS, Knudsen BE, Geiger JD, Brownstone RM, Nath A. Human immunodeficiency virus type 1 tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity. Ann Neurol 1995;37:373-80. PMID 7695237
140: Mah V, Vartavarian LM, Akers MA, Vinters HV. Abnormalities of peripheral nerve in patients with human immunodeficiency infection. Ann Neurol 1988;24:713-7. PMID 2849921
141: Makela P, Howe L, Glover S, Ferguson I, Pinto A, Gompels M. Recurrent Guillain-Barre syndrome as a complication of immune reconstitution in HIV. J Infect 2002;44:47-9. PMID 11972420
142: Malamut RI, Leopald, Parry GJ. The treatment of HIV-associated chronic inflammatory demyelinating polyneuropathy (HIV-CIDP) with intravenous immunoglobulin (IVIG). Neurology 1992;42(suppl 3):335.
143: Manji H. Neuropathy in HIV infection. Curr Opin Neurol 2000;13:589-92. PMID 11073368
144: Marcus K, Truffa M, Boxwell D, et al. Recently identified adverse events secondary to NRT1 therapy in HIV-infected individuals: Cases from the FDA’s adverse event reporting system (AERS). 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA 2002.
145: Martin C, Solders G, Sonnerborg A, Hansson P. Antiretroviral therapy may improve sensory function in HIV-infected patients: a pilot study. Neurology 2000;54:2120-7. PMID 10851375
146: McArthur JC. Neurologic manifestations of AIDS. Medicine 1987;66:407-8. PMID 3316921
147: McArthur JC, Yiannoutsos C, Simpson DM, et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. Neurology 2000;54:1080-8. PMID 10720278
148: Miller JR, Barrett RE, Britton CB, et al. Progressive multifocal leukoencephalopathy in a male homosexual with T-cell immune deficiency. N Engl J Med 1982;307:1436-8. PMID 6290887
149: Miller RG, Parry GJ, Pfaeffl W, Lang W, Lippert R, Kiprov D. The spectrum of peripheral neuropathy associated with ARC and AIDS. Muscle Nerve 1988;11:857-63. PMID 2845264
150: Miller RG, Storey JR, Greco CM. Ganciclovir in the treatment of progressive AIDS-related polyradiculopathy. Neurology 1990;40:569-74. PMID 2157172
151: Moodley K, Patel VB, Moodley AA, et al. Nodal-paranodal antibodies in HIV-immune mediated radiculo-neuropathies: clinical phenotypes and relevance. J Peripher Nerv Syst 2023;28(4):578-85. PMID 37676746
152: Moog C, Kuntz-Simon G, Caussin-Schwemling C, Obert G. Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels. J Gen Virol 1996;196:496-505. PMID 8810995
153: Moore RD, Wong WM, Keruly JC, McArthur JC. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hyroxyurea. AIDS 2000;14:273-8. PMID 10716503
154: Morgello S, Estanislao L, Simpson D, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy. Arch Neurol 2004;61:546-51. PMID 15096404
155: Moulignier A, Authier FJ, Baudrimont M, et al. Peripheral neuropathy in human immunodeficiency virus-infected patients with the diffuse infiltrative lymphocytosis syndrome. Ann Neurol 1997;41:438-45. PMID 9124800
156: Murr AH, Benecke JE. Association of facial paralysis with HIV positivity. Am J Otology 1991;12:450-1. PMID 1805637
157: Nagano I, Shapshak P, Yoshioka M, Xin K, Nakamura S, Bradley WG. Increased NADP-diaphorase reactivity and cytokine expression in dorsal root ganglia in acquired immunodeficiency syndrome. J Neurol Sci 1996;136:117-28. PMID 8815158
158: Nakamoto BK, McMurtray A, Davis J, et al. Incident neuropathy in HIV-infected patients in HAART. AIDS Res Hum Retroviruses 2010;26(7):759-65. PMID 20624077
159: Newman NJ, Lessell S. Bilateral optic neuropathies with remission in two HIV positive men. J Clin Neuro-ophthalmol 1992;12:1-5. PMID 1532592
160: Newshan G. HIV neuropathy treated with gabapentin. AIDS 1998;12:219-21. PMID 9468374
161: Ngassa Mbenda HG, Wadley A, Lombard Z, Cherry C, Price P, Kamerman P. Genetics of HIV-associated sensory neuropathy and related pain in Africans. J Neurovirol 2017;23(4):511-9. PMID 28560631
162: Nikolaidis I, Karakasi MV, Pilalas D, et al. Association of cytokine gene polymorphisms with peripheral neuropathy susceptibility in people living with HIV in Greece. J Neurovirol 2023;29(5):626-39. PMID 37695541
163: Oberlin F, Alcaix A, Rosenheim M, et al. Aspects rhumatologiques des infections par le virus de l’immunodéficience humaine. Semin Hop Paris 1989;65:144-50.
164: Pahwa S, Pahwa R, Saxinger C, Gallo RC, Good RA. Influence of the human T-lymphotropic virus: Evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations. Proc Natl Acad Sci USA 1985;82:8198-202. PMID 2999797
165: Patterson TA, Schmued LC, Sandberg JA, Slikker W. Temporal development of 2’,3’-dideoxyinosine (ddI)-induced peripheral myelinopathy. Neurotoxicol Teratol 2000;22:429-34. PMID 10840187
166: Peters RP, Van Ramshorst MS, Struthers HE, McIntyre JA. Clinical assessment of peripheral neuropathy in HIV-infected children on antiretroviral therapy in rural South Africa. Eur J Pediatr 2014;173(9):1245-8. PMID 24691679
167: Pettersen JA, Jones G, Worthington C, et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol 2006;59:816-24. PMID 16634006
168: Phillips TJ, Cherry CL, Cox S, et al. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS ONE 2010;5(12):e14433. PMID 21203440
169: Piette AM, Tusseau F, Vignon D, et al. Acute neuropathy coincidence with seroconversion for anti-LAV/HTLV-III. Lancet 1986;1:852. PMID 2870330
170: Piliero PJ, Estanislao L, Simpson D. Diaphragmatic paralysis due to isolated phrenic neuropathy in an HIV-infected man. Neurology 2004;62:154-5. PMID 14718726
171: Pillay S, Aldous C, Mahomed F. A deadly combination - HIV and diabetes mellitus: Where are we now? S Afr Med J 2016;106(4):54. PMID 27032854
172: Polydefkis M, Yiannoutsos CT, Cohen BA, et al. Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy. Neurology 2002;58:115-9. PMID 11781415
173: Przedborski S, Liesnard C, Voordecker P, et al. Inflammatory demyelinating polyradiculoneuropathy associated with human immunodeficiency virus infection. J Neurol 1988;235:359-61. PMID 3171617
174: Pu H, Tian J, Flora G, et al. HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Mol Cell Neurosci 2003;24:224-37. PMID 14550782
175: Rappaport J, Joseph J, Croul S, et al. Molecular pathway involved in HIV-1-induced CNS pathology: role of viral regulatory protein, Tat. J Leukoc Biol 1999;65:458-65. PMID 10204574
176: Riggs JE, Rogers JS 2nd, Schochet SS Jr, Gutmann L. AIDS-Related Neuropathy. W Virg Med Journal 1987;83:167-9.
177: Robertson KR, Stern RA, Hall CD, et al. Vitamin b12 deficiency and nervous system disease in HIV infection. Arch Neurol 1993;50:807-11. PMID 8352665
178: Robinson-Papp J, Gonzalez-Duarte A, Simpson DM, et al. The roles of ethnicity and antiretrovirals in HIV-associated polyneuropathy: a pilot study. J Acquir Immune Defic Syndr 2009;51(5):569-73. PMID 19521250
179: Robinson-Papp J, Nmashie A, Pedowitz E, et al. Vagal dysfunction and small intestinal bacterial overgrowth: novel pathways to chronic inflammation in HIV. AIDS 2018;32(9):1147-56. PMID 29596112
180: Robinson-Papp J, Simpson DM. Neuromuscular diseases associated with HIV-1 infection. Muscle Nerve 2009;(40):1043-53. PMID 19771594
181: Roda RH, Bargiela D, Chen W, et al. Large mitochondrial DNA deletions in HIV sensory neuropathy. Neurology 2021;97(2):e156-65. PMID 33947785
182: Romanelli F, Jennings HR, Nath A, Ryan M, Berger J. Therapeutic dilemma: the use of anticonvulsants in HIV-positive individuals. Neurology 2000;54:1404-7. PMID 10751246
183: Rosso R, Di Biagio A, Ferrazin A, Bassetti M, Ciravegna BW, Bassetti D. Fatal lactic acidosis and mimicking Guillain-Barre syndrome in an adolescent with human immunodeficiency virus infection. Pediatr Infect Dis J 2003;22:668-9. PMID 12886900
184: Roullet E, Assuerus V, Gozlan J, et al. Cytomegalovirus multifocal neuropathy in AIDS: Analysis of 15 consecutive cases. Neurology 1994;44:2174-82. PMID 7969979
185: Ruttimann S, Hilti P, Spinas GA, Dubach UC. High frequency of human immunodeficiency virus-associated autonomic neuropathy and more severe involvement in advanced stages of human immunodeficiency virus disease. Arch Intern Med 1991;15:2441-3. PMID 1747000
186: Sacktor N, Nakasujja N, Skolasky RL, et al. Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology 2009;72:165-70. PMID 19139369
187: Safri AY, Gaff J, Octaviana F, et al. Brief report: demographic and genetic associations with markers of small and large fiber sensory neuropathy in HIV patients treated without stavudine. J Acquir Immune Defic Syndr 2020;85(5):612-6. PMID 32925363
188: Said G, Lacroix C, Chemouilli P, et al. Cytomegalovirus neuropathy in acquired immunodeficiency syndrome: a clinical and pathological study. Ann Neurol 1991;29:139-46. PMID 1849386
189: Said G, Lacroix-Ciaudo C, Fujimura H, Blas C, Faux N. The peripheral neuropathy of necrotizing arteritis: a clinicopathological study. Ann Neurol 1988;23:461-5. PMID 2839104
190: Sasaki MG, Leite PG, Leite AG, de Almeida SM. Bilateral peripheral facial palsy secondary to lymphoma in a patient with HIV/AIDS: a case report and literature review. Braz J Infect Dis 2002;6:50-4. PMID 11980604
191: Sawyer MH. Treatment and prevention of varicella-zoster virus infections. In: Straus SE, moderator. Varicella-Zoster Virus Infections: Biology, Natural History, Treatment and Prevention. Ann Intern Med 1988;1008:229-34.
192: Saylor D, Nakigozi G, Nakasujja N, et al. Peripheral neuropathy in HIV-infected and uninfected patients in Rakai, Uganda. Neurology 2017;89(5):485-91. PMID 28679596
193: Schifitto G, McDermott MP, McArthur JC, et al. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002;58:1764-8. PMID 12084874
194: Schifitto G, McDermott MP, McArthur JC, et al. Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology 2005;64(5):842-8. PMID 15753420
195: Schifitto G, Yiannoutsos C, Simpson DM, et al. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology 2001;57:1313-6. PMID 11591856
196: Schifitto G, Yiannoutsos CT, Simpson DM, et al. A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy. J Neurovirol 2006;12:328-31. PMID 16966223
197: Selmaj K, Raine CS, Farooq M, Norton WT, Brosnan CF. Cytokine cytotoxicity against oligodendrocytes: apoptosis induced by lymphotoxin. J Immunol 1991;147:1522-9. PMID 1908877
198: Serrano P, Hernandez N, Arroyo JA, et al. Bilateral Bell palsy and acute HIV type 1 infection: report of 2 cases and review. Clin Infect Dis 2007;44:e57-61. PMID 17304442
199: Shah SS, Rodriguez T, McGowan JP. Miller Fisher variant of Guillain-Barré syndrome associated with lactic acidosis and stavudine therapy. Clin Infect Dis 2003;36:e131-3. PMID 12746793
200: Shapshak P, Nagano I, Xin K, et al. HIV heterogeneity and cytokines. Neuropathogenesis. Adv Exp Med Biol 1995;373:225-38. PMID 7668155
201: Shlay JC, Chaloner K, Max MB, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized-controlled trial. JAMA 1998;280:1590-5. PMID 9820261
202: Silvestris F, Williams RC Jr, Dammacco F. Autoreactivity in HIV-1 infection, the role of molecular mimicry. Clin Immunol Immunopath 1995;75:197-205. PMID 7768037
203: Simpson DM, Brown S, Tobias J; NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008;70(24):2305-13. PMID 18541884
204: Simpson DM, Estanislao L, Evans S, et al. HIV-associated neuromuscular weakness syndrome. AIDS 2004;18:1403-12. PMID 15199316
205: Simpson DM, Haidich AB, Schifitto G, et al. Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS 2002;16:407-12. PMID 11834952
206: Simpson DM, Katzenstein D, Haidich B, et al. Plasma carnitine in HIV-associated neuropathy. AIDS 2001;15(16):2207-8. PMID 11684949
207: Simpson DM, McArthur JC, Olney R, et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 2003;60:1508-14. PMID 12743240
208: Simpson DM, Olney R, McArthur JC, Khan A, Godbold J, Ebel-Frommer K. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 2000;54:2115-9. PMID 10851374
209: Simpson DM, Schifitto G, Clifford DB, et al. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology 2010;74:413-20. PMID 20124207
210: Snider WD, Simpson DM, Nielsen S, Gold JW, Metroka CE, Posner JB. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol 1983;14:403-18. PMID 6314874
211: So YT. Clinical subdivision of mononeuropathy multiplex in patients with HIV infection. (Abstract) Neurology 1992;42(suppl 3):409.
212: So YT, Holtzman DM, Abrams DI, Olney RK. Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey. Arch Neurol 1988;45:945-8. PMID 2843154
213: So YT, Olney RK. The natural history of mononeuropathy multiplex and simplex in patients with HIV infection. (Abstract) Neurology 1991;41(suppl 1):375.
214: Stricker RB, Sanders KA, Owen WF, Kiprov DD, Miller RG. Mononeuritis multiplex associated with cryoglobulinemia in HIV infection. Neurology 1992;42:2103-5. PMID 1436518
215: Strigo IA, Keltner JR, Ellis RJ, Simmons AN. Association of painful human immunodeficiency virus distal sensory polyneuropathy with aberrant expectation of pain relief: functional magnetic resonance imaging evidence. Brain Commun 2021;3(4):fcab260. PMID 34859214
216: Swingler S, Easton A, Morris A. Cytokine augmentation of HIV-1 LTR-driven gene expression in neural cells. AIDS Res Hum Retroviruses 1992;8:487-93. PMID 1599755
217: Talpos D, Tien R, Hesselink JR. Magnetic resonance imaging of AIDS-related polyradiculopathy. Neurology 1991;41:1996-7. PMID 1660573
218: Teo EC, Azwra A, Jones RL, Gazzard BG, Nelson M. Guillain-Barre syndrome following immune reconstitution after antiretroviral therapy for primary HIV infection. J HIV Ther 2007;12(3):62-3. PMID 17962793
219: Timtim SH, Simmons AN, Hays C, et al. HIV peripheral neuropathy-related degeneration of white matter tracts to sensorimotor cortex. J Neurovirol 2022;28(4-6):505-13. PMID 36207560
220: Topp KS, Tanner KD, Levine JD. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol 2000;424:563-76. PMID 10931481
221: Tornatore C, Nath A, Amemiya K, Major EO. Persistent human immunodeficiency virus type 1 infection in human fetal glial cells reactivated by T-cell factor(s) or by the cytokines tumor necrosis factor alpha and interleukin-1 beta. J Virol 1991;65:6094-100. PMID 1920627
222: Trimble KC, Goggins MG, Molloy AM, Mulcahy F, Scott JM, Weir DG. Vitamin B12 deficiency is not a cause of HIV-associated neuropathy. AIDS 1993;7:1132-3. PMID 8397956
223: Tyor WR, Wesselingh SL, Griffin JW, McArthur JC, Griffin DE. Unifying hypothesis for the pathogenesis of HIV-associated dementia complex, vacuolar myelopathy, and sensory neuropathy. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:379-88. PMID 7600105
224: Valcour V, Yeh TM, Bartt R, et al. Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection. HIV Med 2009;10(2):103-10. PMID 19200173
225: Vecchio AC, Marra CM, Schouten J, et al. Distal sensory peripheral neuropathy in human immunodeficiency virus type 1-positive individuals before and after antiretroviral therapy initiation in diverse resource-limited settings. Clin Infect Dis 2020;71(1):158-65. PMID 31630166
226: Veilleux M, Paltiel O, Falutz J. Sensorimotor neuropathy and abnormal vitamin b12 metabolism in early HIV infection. Can J Neurol Sci 1995;22:43-6. PMID 7750072
227: Vendrell J, Heredia C, Pujol M, Vidal J, Blesa R, Graus F. Guillian-Barre syndrome associated with seroconversion for HTLV-III. Neurology 1987;37:544. PMID 3469540
228: Villa A, Foresti V, Confalonieri F. Autonomic nervous system dysfunction associated with HIV infection in intravenous heroin users. AIDS 1992;6:85-9. PMID 1543570
229: Villa A, Foresti V, Confalonieri F. Autonomic neuropathy and prolongation of QT interval in human immunodeficiency virus infection. Clin Auton Res 1995;5:48-52. PMID 7780290
230: Wagner JC, Bromberg MB. HIV infection presenting with motor axonal variant of Guillain-Barre syndrome. J Clin Neuromuscul Dis 2007;9(2):303-5. PMID 18090683
231: Wechsler AF, Ho D. Bilateral Bell’s palsy at the time of HIV seroconversion. Neurology 1989;39:747-84. PMID 2710371
232: Wesselingh SL, Glass J, McArthur JC, Griffin JW, Griffin DE. Cytokine dysregulation in HIV-associated neurological disease. Advances in Neuroimmunology 1994;4:199-206. PMID 7874388
233: Wooltorton E. HIV drug stavudine (Zerit, d4T) and symptoms mimicking Guillain-Barré syndrome. Can Med Assoc J 2002;166:1067-8. PMID 12002986
234: Yoshioka M, Shapshak P, Srivastava AK, et al. Expression of HIV-1 and interleukin-6 in lumbosacral dorsal root ganglia of patients with AIDS. Neurology 1994;44(8):1504-5. PMID 7516054
235: Youle M, Osio M, ALCAR Study Group. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med 2007;8:241-50. PMID 17461852
236: Zehender G, Colasante C, Santambrogio S, et al. Increased risk of developing peripheral neuropathy in patients coinfected with HIV-1 and HTLV-2. J Acquir Immune Defic Syndr 2002;31:440-7. PMID 12447016
237: Zhou L, Kitch DW, Evans SR, et al. Correlates of epidermal nerve fiber densities in HIV-associated distal sensory polyneuropathy. Neurology 2007;68:2113-9. PMID 17562831

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Ravindra Kumar Garg DM FRCP

Dr. Garg of King George's Medical University in Lucknow, India, has no relevant financial relationships to disclose.
See Profile

Editor

Louis H Weimer MD

Dr. Weimer of Columbia University has no relevant financial relationships to disclose.
See Profile

Former Authors

Russell L Chin MD, Naomi Feuer MD, Thomas H Brannagan III MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: male=female
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Peripheral nerve complications of HIV-1 infection

Associated Disorders

autonomic neuropathy
cytomegalovirus infection
distal polyneuropathy
distal polyneuropathy
inflammatory demyelinating polyneuropathy
- mononeuritis multiplex
- mononeuropathy
- plexopathy
- polyradiculopathy

Differential Diagnosis

acute demyelinating polyneuropathy
Guillain-Barre syndrome
mononeuropathies
distal sensory polyneuropathy
HIV-related lumbosacral radiculopathy
- cytomegalovirus polyradiculopathy
- cytomegalovirus-induced mononeuritis multiplex
- medication-related neuropathy
- autonomic neuropathy
- CIDP
- mononeuritis multiplex
- peripheral neuropathy in diffuse infiltrative lymphocytosis syndrome
- syphilitic polyradiculopathy
- hepatitic C neuropathy
- HTLV type I neuropathy
- motor neuron disease syndrome

Also Relevant

Congenital HIV-1 infection
Headache associated with HIV and AIDS
HIV-associated dementia
HIV-associated neurocognitive disorders
Viral and retroviral myositis

Clinical Categories

Peripheral Neuropathies

Peripheral nerve complications of HIV-1 infection …

Peripheral nerve complications of HIV-1 infection

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Prevention

Differential diagnosis

Diagnostic workup

Management

Outcomes

References

Contributors

Author

Editor

Former Authors

Patient Profile

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Leukodystrophies

Neurolymphomatosis

Spinal accessory neuropathy

Thallium neuropathy

Bell palsy

Acute autonomic neuropathies

Tibial nerve injuries

Acute inflammatory demyelinating polyradiculoneuropathy

Peripheral nerve complications of HIV-1 infection

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Prevention

Differential diagnosis

Diagnostic workup

Management

Outcomes

References

Contributors

Author

Editor

Former Authors

Patient Profile

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Leukodystrophies

Neurolymphomatosis

Spinal accessory neuropathy

Thallium neuropathy

Bell palsy

Acute autonomic neuropathies

Tibial nerve injuries

Acute inflammatory demyelinating polyradiculoneuropathy

This is an article preview.
Start a Free Account
to access the full version.